CORAL GABLES, FL / ACCESSWIRE / March 8, 2019 / When it comes to discussing healthcare stock market, it goes without saying that the success of the market is directly connected to if companies in the healthcare industry are doing their part to take care of consumers. It is the responsibility of healthcare companies to work to develop innovative treatments and care options for consumers, especially at a time where new diseases are discovered on a frequent basis. As our society evolves, medical professionals are tasked with maintaining the future of our healthcare system. So long as companies in the healthcare industry rise to the occasion, investors looking for opportunities could benefit from looking into healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Tonix Pharmaceuticals Holding Corp (TNXP), Steller Biotechnologies Inc (SBOT), NantHealth Inc (NH) are 4 healthcare companies stepping up their game on Friday.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) made headlines earlier this week when the Company announced that it will be working with NexTech AR solutions to explore bringing augmented reality technology to its patient-centric healthcare app. Through the use of AR as a learning tool in training healthcare professionals, this will create a highly engaging and immersive educational experience which aids in retention and how well complex concepts can be grasped.

Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), commented, "at Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient-centric telemedicine app. AR has the potential to revolutionize both the access to data and the delivery of healthcare."

For More Information On Premier Health Group, Click Here

Tonix Pharmaceuticals Holding Corp (TNXP), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat neuropsychiatric conditions and biological products to improve biodefense, yesterday announced that the European Patent Office (EPO) issued European Patent No. 3246031 to the Company on February 27, 2019. The patent, "Method for Treating Neurodegenerative Dysfunction," claims the use of TNX-601, or tianeptine oxalate and other salts, for treating neurocognitive dysfunction associated with corticosteroid treatment.

Seth Lederman, President, and CEO of Tonix said, "Tianeptine oxalate, or TNX-601, is an important product in our pipeline and is being developed not only for steroid-induced neurocognitive impairment but also as a daytime treatment for a posttraumatic stress disorder."

For More Information On Tonix Pharmaceuticals Holding Corp Inc, Click Here

Stellar Biotechnologies Inc (SBOT) saw its shares enjoy an impressive 35% boost in Friday's trading, with shares trading at $1.62 per share early in the afternoon. The Company today announced that it has executed a share exchange agreement with privately-held Edesa Biotech Inc., a Canadian company, and Edesa's shareholders to create a company focused on the development of innovative therapeutics for dermatological and gastrointestinal indications with clear unmet medical needs.

Per the details of the share exchange agreement, Edesa shareholders have agreed to exchange their shares of Edesa for newly-issued common shares of Stellar. At the closing, Edesa will become a wholly-owned subsidiary of Stellar. Following the closing, current Stellar shareholders are expected to own approximately 10%, and the current shareholders of Edesa are expected to own approximately 90%, of the combined company on a fully-diluted basis, subject to a 2% upward or downward adjustment based upon the amount of Stellar's working capital balance immediately prior to the closing.

For More Information On Stellar Biotechnologies Inc, Click Here

NantHealth Inc (NH) announced in mid-February that the Company would present two posters at the American Society of Clinical Oncology's Genitourinary Cancers Symposium later in the month. NantHealth, in partnership with NantOmics, teamed together to explore the significance of RNA expression and individual biomarkers in determining why some patients do not respond to targeted cancer therapies based on DNA genomic profiling alone.

Following their presentation, Sandeep Reddy, Chief Medical Officer of NantHealth, said, "while next-generation sequencing for advanced cancers has become routine, not all patients are responding to targeted treatments based solely on DNA genomic profiling. It is becoming clear that we must delve deeper into RNA expression, as well as identify key biomarkers, to develop effective cancer treatments and therapies."

For More Information on NantHealth Inc, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.Please click here for full disclaimer.

Contact Information:

news@stockprice.com

SOURCE: StockPrice.com

View source version on accesswire.com:
https://www.accesswire.com/538518/Four-Healthcare-Stocks-Surpassing-Investor-Expectations